ABSTRACT

Hypothetically, mRNA-vaccine-encapsulated-small liposomes and lipid carriers may accumulate through the permeation retention and enhanced effect in tumor tissues. The recommendation that have been suggested administering COVID-19 vaccines one to two weeks prior to a chemotherapy dose by many key-professional organizations has not been practical with COVID-19 administration schedules (for examples; two doses of mRNA-1273 (Moderna) are recommended to be given 28 days apart, whereas two doses of BNT162b2 (Pfizer/BioNTech) are given 21 days apart, efficacy > 94%), variable chemotherapeutic regimens, and limited COVID-19 vaccination slot availability, contributing to allowing the most rapid COVID-19 vaccination of these immunosuppressed cancer patients and due to lacking COVID-19- vaccine safety and the information immunogenicity in the context of immune-system-stimulated immunotherapies (for examples; immune checkpoint inhibitor (ICI) therapy) and general exclusion of malignancy-diagnosed patients in the clinical trials of currently approved COVID-19 vaccines.

Keywords

Abbreviations

Introduction
In patients with cancer, SARS-CoV-2 (COVID-19) can contribute to increasing morbidity and mortality [1-3] and decreased survival was found in patients with hematological and intrathoracic malignancies, poor performance status, comorbidities, and increased age [3-5]. Patients with hematological malignancies who were treated with stem cell transplantation and anti-CD-20 antibody demonstrated lower rates of seroconversion, compared to COVID-19-infected-cancer patients [6, 7]. Patients with hematological malignancies might have substantially compromised B-cell and T-cell responses [8]. These study results indicated that following COVID-19 vaccination, overall high seroconversion rates could be anticipated in cancer patients due to different mechanisms and degrees of immune suppression, such as cell therapies (particularly chimeric antigen receptor (CAR)-T cell), anti-CD-20 antibody (B-cell depleting) therapies, stem cell transplantation, immunosuppressive effects of corticosteroid treatment, and cytotoxic-chemotherapy-bone-marrow-suppressive effects in certain subgroups of cancer patients [9]. Currently, there are lacking data in cancer patients in protection following SARS-CoV-2 (COVID-19) infection, reinfection by various SARS-CoV-2 (COVID-19) variants, or COVID-19 vaccination although mucosal
surface antigens (e.g., IgA and protective T-cell responses) might be similarly important in protection from natural SARS-CoV-2 (COVID-19) infection [10]. The association of carcinogenesis with genomic information encoding vaccines, particularly with very-transient-intracellular-presence-COVID-19-mRNA vaccines is likely very low [11].

**mRNA Vaccination in Patients with Anti-cancer Therapeutics**

Hypothetically, mRNA-vaccine-encapsulated-small liposomes and lipid carriers may accumulate through the permeation retention and enhanced effect in tumor tissues [12, 13]. The recommendation that have been suggested administering COVID-19 vaccines one to two weeks prior to a chemotherapy dose by many key-professional organizations has not been practical with COVID-19 administration schedules (for examples; two doses of mRNA-1273 (Moderna) are recommended to be given 28 days apart, whereas two doses of BNT162b2 (Pfizer/BioNTech) are given 21 days apart, efficacy > 94 %), variable chemotherapeutic regimens, and limited COVID-19 vaccination slot availability, contributing to allowing the most rapid COVID-19 vaccination of these immunosuppressed cancer patients [14] and due to lacking COVID-19 vaccine safety and the information immunogenicity in the context of immune-system-stimulated immunotherapies (for examples; immune checkpoint inhibitor (ICI) therapy) [15] and general exclusion of malignancy-diagnosed patients in the clinical trials of currently approved COVID-19 vaccines [16].

In convalescent-COVID-19 patients, neutralizing antibody, memory B and memory T cells specific to SARS-CoV-2 (COVID-19) have been identified after six months of infection [17-19] and both antibody production and memory CD4+ T-cells sustained several months after SARS-CoV-2 (COVID-19) infection in rapidly resolved-symptom individuals [20]. Humoral and cell-mediated immunity to SARS-CoV-2 (COVID-19) are the integrated highly-effective-durable-protective key [21]. Antibody-dependent enhancement (ADE) of disease, mediated by virus-binding antibodies and do not neutralize the virus takes two main virus-binding forms (one form in dengue virus infection by virus-binding antibody and the internalization of the antibody-virus complex through interaction with Fc-gamma receptor into replicated macrophages; the other form, non-neutralizing antibodies mediate the formation of incited-inflammation-immune complex) has been proposed as a COVID-19 vaccine-design concern due to high levels of antibodies in in vitro observations and in patients with severe COVID-19 with SARS-CoV-2 (COVID-19) taken-up macrophages [22]. No compelling evidence of ADE from convalescent plasma has been found [23-25]. Theoretically, ADE is reduced by elicited-antibody-response-on-neutralizing-epitope-COVID-19 vaccines [21].

Inability to integrate into host genome, delivery into cytoplasm, avoidance of anti-vector immunity, eliciting strong humoral and cellular immunity, avoidance of introduction of pathogen, and easier to mass-production are the advantages of mRNA vaccines, whereas the requirement of lipid nanoparticle for delivery, easy degradation, and freezing storage are their disadvantages [21].

**Previous Involved Studies**

In the USA, a study of 273,00 cancer-diagnosed patients (total of 73 million patients) that 16,570 patients were diagnosed of COVID-19 demonstrated the increased number of COVID-19-infected cancer patients with adjusted OR of 7 [26]. COVID-19 patients with recently diagnosed leukemia, non-Hodgkin lymphoma, and lung cancer were highest odds of COVID-19 infection with adjusted OR of 12.2, 8.5, and 7.7, respectively [26] and demonstrated the greater risk of mortality (14.9 %) among COVID-19-infected-cancer patients, compared to COVID-19 patients without cancer (5.3 %) and cancer patients without COVID-19 infection (4.0 %) [26], whereas hematological-malignancy-diagnosed patients had increased risk of mortality at least 2.5 times, compared to patients with other cancers (at least 1.2 times) [27].

Cancer patients with COVID-19 vaccination undergoing chemotherapy, with exception of during periods of intensive chemotherapy are expected to generate COVID-19-protective responses that are similar to inactivated influenza [28, 29], pneumococcal polysaccharide, and hepatitis subunit [29,30] vaccinations. Cancer patients being treated with targeted therapies (tyrosine kinase inhibitors (TKIs) (erlotinib, imatinib, sunitinib, or monoclonal antibodies (trastuzumab, etc.)) are reasonably expected generating protective responses with COVID-19 vaccination [21]. Cancer patients on ICI therapy are expected to produce protective responses following COVID-19 vaccination due to low risk of immune-related adverse events (IRAEs) found in cancer patients with ICI therapy receiving influenza vaccination [21,31,32]. In some settings, delaying ICI treatment in cancer patients may be safe from a perspective of cancer treatment [33]. Practically, cancer patients treated with lymphodepleting or anti-B cell or anti-CD19 therapy or plasma-cell-depleting therapy are recommended to receive vaccination or COVID-19 vaccination at least 6 months after therapies [28,30].

Sometimes, they may be flexible to optimize the timing of COVID-19 vaccinations (for example; COVID-19 vaccination followed by anti-B cell therapy several weeks later) depending on the urgency and phase of a cancer treatment in a patient [21]. Cancer patients on radiation therapy, particularly total body irradiation (TBI) that usually is given to spine and total lymph nodes for bone marrow suppression prior to other rare situations or stem cell transplantation should be COVID-19 vaccinated to produce protective immunity responses [21]. Cancer patients receiving mRNA vaccines are not specifically anticipated safety concerns [21]. Generally, live vaccines, particularly live COVID-19 vaccines are not recommended in cancer patients ongoing cytotoxic, lymphodepleting, or targeted therapies [28-30]. COVID-19 vaccination has been recommended after approval of BNT162b2 (Pfizer) vaccine in cancer patients by the American Association for Cancer Research’s (AACR’s) COVID-19 and cancer task force [34], American Society of Clinical Oncology (ASCO) [35], European Society for Medical Oncology (ESMO) [36], Infectious Disease Society of America (IDSA) [35], National Comprehensive Cancer Network (NCCN) COVID-19 vaccination advisory committee [21], Society of Immunotherapy of Cancer [37],
and the United States Centers for Disease Control and Prevention (US CDC) [21]. COVID-19 vaccination is strongly recommended in cancer patients, including their caregivers, whereas exactly representative data are not available, benefits likely outweigh risks of COVID-19 [21]. Immunization or COVID-19 vaccination in cancer patients undergoing adoptive cell therapy or organ transplantation should be delayed at least 3 months to maximize vaccine efficacy [21,38]. In patients with breast cancer, screening examinations of transient lymphadenopathy from COVID-19 vaccination should be performed either before first dose or 4-6 weeks after the second dose of a COVID-19 vaccine [39,40].

Conclusion
For continuation of the quality of oncological care, cancer patients on clinical trials should be prioritized for COVID-19 vaccination that do not affect the eligibility of the clinical trials.

References
29. Mukulka M, Cesaro S, de Lavallade H, et al. Vaccination of patients with hematological malignancies who did not have transplantations: guidelines from the 2017 European...


